AUM Biosciences
June 16, 2025
Company Presentation
Oncology
154
AUM Biosciences is a Singapore-based clinical-stage biotech company focused on developing precision oncology therapeutics. Founded in 2018, AUM is committed to addressing unmet medical needs in cancer treatment, particularly in Asia, by targeting drug resistance and biologically relevant cancer pathways. The company leverages biomarker-driven strategies, innovative trial designs, and digital tools to accelerate drug development. Its pipeline includes small molecule therapies aimed at "undruggable"cancer targets. AUM is led by a seasoned team with extensive experience in oncology drug development.
Company HQ City:
10 Anson Rd
#24-16A/B
International Plaza,
Singapore 079903
Company HQ State:
10 Anson Rd
#24-16A/B
International Plaza,
Singapore 079903
Company HQ Country:
Singapore
Year Founded:
2018
Lead Product in Development:
Tinodasertib
CEO
Vishal Doshi
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
AUM001, AUM302 and AUM601
When you expect your next catalyst update?
AUM001 Data read out for MSS CRC, IND for AUM302.
What is your next catalyst (value inflection) update?
AUM001 Data read out (Q3 2025), AUM302 IND (Q1 2026)
Website
ww.aumbiosciences.com
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}